GEA
JAZZ icon

Glen Eagle Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Glen Eagle Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14
Closed -$2.49K – 1076
2021
Q2 		$2.49K Buy
+14
New +$2.42K ﹤0.01% 898

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Glen Eagle Advisors's JAZZ Position: Q3 2021 in Review

Glen Eagle Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2021, closing a stake of 14 shares — an estimated $2.49K sold.

Glen Eagle Advisors first reported a position in JAZZ in Q2 2021 and held it in 1 quarter. The position peaked at $2.49K in Q2 2021. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.

  • Glen Eagle Advisors reported no remaining Jazz Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Glen Eagle Advisors sold 14 Jazz Pharmaceuticals shares in Q3 2021, an estimated $2.49K.
  • Glen Eagle Advisors first reported a position in Jazz Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Glen Eagle Advisors's Jazz Pharmaceuticals position peaked at $2.49K in Q2 2021.
  • 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.

Based on Glen Eagle Advisors's 13F filing for Q3 2021, filed 13 Aug 2024.